NCT06654297 2024-12-11Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasWest China HospitalPhase 1 Recruiting6 enrolled
NCT05865132 2023-05-18Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting30 enrolled